1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Genetic conditions
  5. Cystic fibrosis

Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

Technology appraisal guidance [TA276] Published date: 27 March 2013

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
  • Share
    • Share
    • Linked In
    • Twitter
    • Facebook
    • Email
    • More...

Information for the public


  • Colistimethate sodium and tobramycin dry powders for inhalation for pseudomonas lung infection in cystic fibrosis 27 March 2013   PDF 185.03 KB
  • Gwybodaeth i'r cyhoedd 07 October 2013   Word 337.5 KB
NICE
  • About NICE
  • Into practice
  • News
  • Contact us
  • Leave feedback
  • Jobs
  • Newsletters and alerts
  • Blog
  • Twitter
  • YouTube
  •   Facebook
  • LinkedIn

Explore

  • Guidance
  • Pathways
  • Standards and indicators
  • Savings and productivity
  • Evidence search
  • BNF
  • BNFC
  • Clinical knowledge summaries
  • Journals and databases

Reusing our content

  • Reuse information
  • NICE UK Open Content Licence

Guidance app

  • Android
  • iOS

Get involved

  • Register as a stakeholder
  • Citizens council
  • Consultations
  • Fellows and scholars
  • Join a committee
  • Meetings in public
  • Student champions
  • Tenders
  • Public involvement
  • Accessibility
  • Freedom of information
  • Syndication services
  • Glossary
  • Terms and conditions

Copyright © 2017 National Institute for Health and Care Excellence. All rights reserved.